无进展生存期-话题@MedSci

#无进展生存期#

56篇内容 | 2199人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1459655, encodeId=6f6d145965554, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=默沙东PD-1免疫疗法Keytruda一线治疗晚期非小细胞肺癌（NSCLC）显著延长总生存期和无进展生存期, objectType=article, longId=71400, objectId=0e3be140052, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e3be140052, replyNumber=0, likeNumber=75, createdTime=2016-06-23, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e3be140052, moduleTitle=默沙东PD-1免疫疗法Keytruda一线治疗晚期非小细胞肺癌（NSCLC）显著延长总生存期和无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0e3be140052)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459654, encodeId=979a145965441, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=EHA 2016：强生多发性骨髓瘤药物Darzalex+来那度胺+地塞米松三联疗法III期临床显著延长无进展生存期, objectType=article, longId=70647, objectId=2a45e0647b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a45e0647b2, replyNumber=0, likeNumber=76, createdTime=2016-06-15, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a45e0647b2, moduleTitle=EHA 2016：强生多发性骨髓瘤药物Darzalex+来那度胺+地塞米松三联疗法III期临床显著延长无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2a45e0647b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459653, encodeId=47b21459653b8, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=Lancet：olaratumab联合阿霉素可显著改善晚期或转移性软组织肉瘤患者的无进展生存期, objectType=article, longId=70568, objectId=b217e05681b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b217e05681b, replyNumber=0, likeNumber=63, createdTime=2016-06-14, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b217e05681b, moduleTitle=Lancet：olaratumab联合阿霉素可显著改善晚期或转移性软组织肉瘤患者的无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b217e05681b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459652, encodeId=6a1c14596522f, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=NEJM：口服Ixazomib、来那度胺、地塞米松治疗可显著延长多发性骨髓瘤患者的无进展生存期（TOURMALINE-MM1研究）, objectType=article, longId=67240, objectId=9d3e6e240f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9d3e6e240f2, replyNumber=0, likeNumber=79, createdTime=2016-04-29, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9d3e6e240f2, moduleTitle=NEJM：口服Ixazomib、来那度胺、地塞米松治疗可显著延长多发性骨髓瘤患者的无进展生存期（TOURMALINE-MM1研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9d3e6e240f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459651, encodeId=d761145965153, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=ASH 2015：免疫调节单抗elotuzumab持续改善多发性骨髓瘤无进展生存期, objectType=article, longId=60415, objectId=514f6041501, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=514f6041501, replyNumber=0, likeNumber=56, createdTime=2015-12-10, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=514f6041501, moduleTitle=ASH 2015：免疫调节单抗elotuzumab持续改善多发性骨髓瘤无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=514f6041501)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459650, encodeId=3f0d14596502b, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=诺华白血病药物Arzerra III期临床显著改善复发性CLL无进展生存期, objectType=article, longId=52073, objectId=0df1520e32c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0df1520e32c, replyNumber=0, likeNumber=64, createdTime=2015-06-17, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0df1520e32c, moduleTitle=诺华白血病药物Arzerra III期临床显著改善复发性CLL无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0df1520e32c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459649, encodeId=8ee41459649b6, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=Lancet Oncol：Ombrabulin+cisplatin显著提高软组织肉瘤的无进展生存期, objectType=article, longId=50458, objectId=f1ef504589c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f1ef504589c, replyNumber=0, likeNumber=74, createdTime=2015-05-10, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f1ef504589c, moduleTitle=Lancet Oncol：Ombrabulin+cisplatin显著提高软组织肉瘤的无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f1ef504589c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459648, encodeId=8393145964810, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=JCO：舒尼替尼维持治疗可改善小细胞肺癌无进展生存期PFS（II期研究）, objectType=article, longId=50196, objectId=b7285019648, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b7285019648, replyNumber=0, likeNumber=0, createdTime=2015-05-06, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b7285019648, moduleTitle=JCO：舒尼替尼维持治疗可改善小细胞肺癌无进展生存期PFS（II期研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b7285019648)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459647, encodeId=1f43145964e3a, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=BMC Cancer：FGFR1和FRS2α的表达增加会降低RCC患者的无进展生存期, objectType=article, longId=50059, objectId=70ba50059c4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=70ba50059c4, replyNumber=0, likeNumber=89, createdTime=2015-05-01, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=70ba50059c4, moduleTitle=BMC Cancer：FGFR1和FRS2α的表达增加会降低RCC患者的无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=70ba50059c4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459646, encodeId=f6041459646eb, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=NEJM：克唑替尼(Crizotinib)一线治疗ALK阳性的非鳞癌NSCLC患者显著延长无进展生存期, objectType=article, longId=43675, objectId=ea41436e517, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ea41436e517, replyNumber=0, likeNumber=74, createdTime=2014-12-07, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ea41436e517, moduleTitle=NEJM：克唑替尼(Crizotinib)一线治疗ALK阳性的非鳞癌NSCLC患者显著延长无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ea41436e517)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459645, encodeId=acec1459645a5, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=GSK单抗药Arzerra III期显著改善复发性CLL无进展生存期, objectType=article, longId=38613, objectId=afb438613a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=afb438613a7, replyNumber=0, likeNumber=54, createdTime=2014-08-06, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=afb438613a7, moduleTitle=GSK单抗药Arzerra III期显著改善复发性CLL无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=afb438613a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459644, encodeId=5b6c145964492, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=索拉非尼不能延长HER2阴性乳腺癌患者无进展生存期（RESILIENCE研究）, objectType=article, longId=38348, objectId=af3d38348b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=af3d38348b5, replyNumber=0, likeNumber=67, createdTime=2014-07-30, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=af3d38348b5, moduleTitle=索拉非尼不能延长HER2阴性乳腺癌患者无进展生存期（RESILIENCE研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=af3d38348b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459643, encodeId=c7141459643dc, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=Lancet Oncol：伏力诺他联合硼替佐米治疗能延长多发性骨髓瘤患者的无进展生存期, objectType=article, longId=24998, objectId=a2c924998e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a2c924998e6, replyNumber=0, likeNumber=58, createdTime=2013-09-27, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a2c924998e6, moduleTitle=Lancet Oncol：伏力诺他联合硼替佐米治疗能延长多发性骨髓瘤患者的无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a2c924998e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459642, encodeId=456e145964245, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=他汀或可改善炎性乳癌患者无进展生存期, objectType=article, longId=12956, objectId=f88212956fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f88212956fb, replyNumber=0, likeNumber=71, createdTime=2012-12-14, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f88212956fb, moduleTitle=他汀或可改善炎性乳癌患者无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f88212956fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459641, encodeId=464014596411a, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=标准治疗方案中加入阿瓦斯汀可显著延长初诊侵袭性胶质瘤的无进展生存期（AVAglio研究）, objectType=article, longId=11325, objectId=b81e1132569, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b81e1132569, replyNumber=0, likeNumber=62, createdTime=2012-11-28, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b81e1132569, moduleTitle=标准治疗方案中加入阿瓦斯汀可显著延长初诊侵袭性胶质瘤的无进展生存期（AVAglio研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b81e1132569)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459640, encodeId=ad09145964012, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=加用贝伐珠单抗可使难治性卵巢癌无进展生存期延长1倍, objectType=article, longId=6774, objectId=daab6e74a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=daab6e74a5, replyNumber=0, likeNumber=70, createdTime=2012-06-07, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=daab6e74a5, moduleTitle=加用贝伐珠单抗可使难治性卵巢癌无进展生存期延长1倍, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=daab6e74a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459639, encodeId=f66614596390f, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=苯达莫司汀-利妥昔单抗可使惰性淋巴瘤无进展生存期翻番, objectType=article, longId=6773, objectId=4b166e73df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4b166e73df, replyNumber=0, likeNumber=110, createdTime=2012-06-07, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4b166e73df, moduleTitle=苯达莫司汀-利妥昔单抗可使惰性淋巴瘤无进展生存期翻番, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4b166e73df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459638, encodeId=ed3f145963893, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=NEJM：阿瓦斯汀仅能延长晚期卵巢癌患者无进展生存期1-4个月, objectType=article, longId=3666, objectId=597d366685, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=597d366685, replyNumber=0, likeNumber=63, createdTime=2012-01-08, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=597d366685, moduleTitle=NEJM：阿瓦斯汀仅能延长晚期卵巢癌患者无进展生存期1-4个月, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=597d366685)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

无进展生存期

2020-05-29

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

默沙东PD-1免疫疗法Keytruda一线治疗晚期非小细胞肺癌（NSCLC）显著延长总生存期和无进展生存期

2016-06-23

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

EHA 2016：强生多发性骨髓瘤药物Darzalex+来那度胺+地塞米松三联疗法III期临床显著延长无进展生存期

2016-06-15

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

Lancet：olaratumab联合阿霉素可显著改善晚期或转移性软组织肉瘤患者的无进展生存期

2016-06-14

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

NEJM：口服Ixazomib、来那度胺、地塞米松治疗可显著延长多发性骨髓瘤患者的无进展生存期（TOURMALINE-MM1研究）

2016-04-29

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

ASH 2015：免疫调节单抗elotuzumab持续改善多发性骨髓瘤无进展生存期

2015-12-10

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

诺华白血病药物Arzerra III期临床显著改善复发性CLL无进展生存期

2015-06-17

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

Lancet Oncol：Ombrabulin+cisplatin显著提高软组织肉瘤的无进展生存期

2015-05-10

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

JCO：舒尼替尼维持治疗可改善小细胞肺癌无进展生存期PFS（II期研究）

2015-05-06

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

BMC Cancer：FGFR1和FRS2α的表达增加会降低RCC患者的无进展生存期

2015-05-01

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

NEJM：克唑替尼(Crizotinib)一线治疗ALK阳性的非鳞癌NSCLC患者显著延长无进展生存期

2014-12-07

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

GSK单抗药Arzerra III期显著改善复发性CLL无进展生存期

2014-08-06

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

索拉非尼不能延长HER2阴性乳腺癌患者无进展生存期（RESILIENCE研究）

2014-07-30

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

Lancet Oncol：伏力诺他联合硼替佐米治疗能延长多发性骨髓瘤患者的无进展生存期

2013-09-27

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

他汀或可改善炎性乳癌患者无进展生存期

2012-12-14

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

标准治疗方案中加入阿瓦斯汀可显著延长初诊侵袭性胶质瘤的无进展生存期（AVAglio研究）

2012-11-28

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

加用贝伐珠单抗可使难治性卵巢癌无进展生存期延长1倍

2012-06-07

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

苯达莫司汀-利妥昔单抗可使惰性淋巴瘤无进展生存期翻番

2012-06-07

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

NEJM：阿瓦斯汀仅能延长晚期卵巢癌患者无进展生存期1-4个月

2012-01-08

科室
- - 订阅+
  - 更多科室
工具
服务